Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

2.86USD
20 Jul 2018
Change (% chg)

$-0.12 (-4.03%)
Prev Close
$2.98
Open
$2.98
Day's High
$3.00
Day's Low
$2.84
Volume
156,957
Avg. Vol
271,815
52-wk High
$5.66
52-wk Low
$2.60

Latest Key Developments (Source: Significant Developments)

Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy
Monday, 26 Feb 2018 06:05am EST 

Feb 26 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY.ACHILLION - ‍EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS ISSUED POSITIVE OPINION ON ACH-4471 FOR ORPHAN STATUS IN EU FOR C3 GLOMERULOPATHY​ TREATMENT.  Full Article

Achillion Forecasts 2018 Loss Of $0.55-$0.58 Per Share
Thursday, 22 Feb 2018 06:05am EST 

Feb 22 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY; ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS.SEES FY 2018 LOSS PER SHARE $0.55 TO $0.58.JOSEPH TRUITT, CHIEF OPERATING OFFICER, PROMOTED TO PRESIDENT OF ACHILLION.SEEKING TO GENERATE ADDITIONAL DATASETS WITH ACH-4471 IN BOTH C3G AND PNH PROGRAMS IN 2018.RESTRUCTURING WILL REDUCE COMPANY'S WORKFORCE BY APPROXIMATELY 20% TO APPROXIMATELY 70 EMPLOYEES..ACHILLION - RESTRUCTURING PLAN EXPECTED TO DELIVER ABOUT $10 MILLION OF SAVINGS IN 2018 OVER 2017 EXPENSE LEVELS.FY2018 EARNINGS PER SHARE VIEW $-0.71 -- THOMSON REUTERS I/B/E/S.ACHILLION - DUE TO RESTRUCTURING, EXPECT RESEARCH AND DEVELOPMENT EXPENSES DURING 2018 WILL BE ABOUT $58 MILLION - $60 MILLION.QTRLY LOSS PER SHARE $0.17.Q4 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.  Full Article

Achillion Initiates Phase I First-In Study Of ACH-5228
Wednesday, 20 Dec 2017 06:05am EST 

Dec 20 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D.ACHILLION PHARMACEUTICALS INC - COMPANY EXPECTS TO REPORT INTERIM CLINICAL DATA FROM STUDY DURING SECOND HALF OF 2018.  Full Article

Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy
Monday, 18 Dec 2017 06:30am EST 

Dec 18 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY.ACHILLION PHARMACEUTICALS INC - INITIATED BIOAVAILABILITY STUDY EVALUATING EXTENDED-RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.ACHILLION PHARMACEUTICALS INC - INITIATION OF BIOAVAILABILITY STUDY OF EXTENDED RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.  Full Article

Achillion announces pricing of secondary offering of common stock
Wednesday, 15 Nov 2017 10:05pm EST 

Nov 15 (Reuters) - Achillion Pharmaceuticals Inc :Achillion announces pricing of secondary offering of common stock.Says secondary public offering of 18.4 million common shares priced at $2.75per share.  Full Article

Achillion announces proposed secondary offering of common stock
Tuesday, 14 Nov 2017 04:03pm EST 

Nov 14 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion announces proposed secondary offering of common stock.Achillion Pharmaceuticals Inc says ‍intends to offer for sale in an underwritten public offering 18.4 million shares of common stock of achillion​.Achillion Pharmaceuticals - existing stockholder of company, Johnson & Johnson Innovation-JJDC Inc will be making the offering of common stock.Achillion Pharmaceuticals Inc - ‍achillion will not sell any shares or receive any proceeds from offering​.  Full Article

Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g
Tuesday, 14 Nov 2017 04:01pm EST 

Nov 14 (Reuters) - Achillion Pharmaceuticals Inc :Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g.Achillion Pharmaceuticals Inc - ‍greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ach-4471​.Achillion Pharmaceuticals Inc - ‍improvement in complement alternative pathway biomarkers observed​.Achillion Pharmaceuticals Inc - ‍preliminary data from phase 2 trial suggest that ach-4471 may reverse ap hyperactivity in c3g​.Achillion Pharma- ‍preliminary data from phase 2 trial suggest ach-4471 may have potential to reverse AP hyperactivity resulting in improvement in proteinuria​.  Full Article

Achillion says ACH-4471 granted orphan drug designation by FDA
Monday, 6 Nov 2017 06:05am EST 

Nov 6 (Reuters) - Achillion Pharmaceuticals Inc :Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria.Achillion Pharma - ‍EMA committee for orphan medicinal products issued a positive opinion on ACH-4471 for orphan status in EU for treatment of PNH​.  Full Article

Achillion Q3 loss per share $0.14
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion reports third quarter 2017 financial results and provides update on clinical programs.Q3 loss per share $0.14.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.  Full Article

RTW Investments reports 5.2 pct passive stake in Achillion Pharmaceuticals - SEC filing‍​
Thursday, 28 Sep 2017 03:09pm EDT 

Sept 28 (Reuters) - RTW Investments LP::RTW Investments LP reports 5.2 percent passive stake in Achillion Pharmaceuticals Inc as of September 18, 2017 - SEC filing‍​.  Full Article

BRIEF-Achillion Pharma Says Truitt Gets Annualized Base Salary Of $560,000

* ACHILLION PHARMACEUTICALS SAYS JOSEPH TRUITT RECEIVES ANNUALIZED BASE SALARY OF $560,000, IN CONNECTION WITH APPOINTMENT AS CEO - SEC FILING